CC
VKTX icon

Centiva Capital’s Viking Therapeutics VKTX Stock Holding History

Centiva Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$390K Hold
10,000
– – ﹤0.01% 1035
2026
Q1 		$325K Buy
+10,000
New +$321K ﹤0.01% 1026

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Centiva Capital's VKTX Position: Q2 2026 in Review

Centiva Capital reduced its Viking Therapeutics (VKTX) stake by 5.7% in Q2 2026, selling an estimated $24.5K and leaving 12,500 shares worth $488K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

Centiva Capital first reported a position in VKTX in Q3 2022 and has held it in 6 quarters since. The position peaked at $3.59M in Q2 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Centiva Capital held 12,500 shares of Viking Therapeutics worth $488K as of Q2 2026.
  • Centiva Capital sold 758 Viking Therapeutics shares in Q2 2026, an estimated $24.5K.
  • Viking Therapeutics made up ﹤0.01% of Centiva Capital's portfolio in Q2 2026, its #932 holding.
  • Centiva Capital first reported a position in Viking Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • Centiva Capital's Viking Therapeutics position peaked at $3.59M in Q2 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.